GastroFISH(TM) is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.
Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.
The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk, Yale researchers report in an abstract presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia, October 17-21.
Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors.
Researchers at The Wistar Institute have identified a key gene (KLF17) involved in the spread of breast cancer throughout the body. They also demonstrated that expression of KLF17 together with another gene (Id1) known to regulate breast cancer metastasis accurately predicts whether the disease will spread to the lymph nodes. Previously, the function of KLF17 had been unknown.
Peregrine Pharmaceuticals, Inc. reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer. Preliminary data at the end of the six planned treatment cycles in the Phase II study showed that 28 of 46, or 61%, of all patients enrolled in the trial achieved an objective tumor response according to RECIST criteria.
Think of a protective fence that blocks the neighbor's dog from charging into your backyard. The body, too, has fences -- physical and biochemical barriers that keep cells in their place.
Sentinel-lymph-node (SLN) mapping and biopsy maintains staging accuracy in early breast cancer and identifies patients for selective lymphadenectomy. SLN mapping requires injection of technetium-99m-sulfur colloid-an effective but sometimes painful method, for which better pain-management strategies are needed, investigators in the United States report.
An NIH-sponsored, multi-year study of hundreds of women diagnosed with breast cancer found that Positron Emission Mammography (PEM) scanners significantly outperform MRI when differentiating between benign and cancerous lesions.
Clemson University researchers in collaboration with researchers at the University of Bremen, Germany, are working to make the physical pain and discomfort of mammograms a thing of the past, while allowing for diagnostic imaging eventually to be done in a home setting.
